Regina Pillai, MD
Pulmonary Disease · Webster, TXNPI 1720273121
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $78,650 of the $94,295 with a category attached, or 83.4%. GSK accounts for 86.1% of it on its own, with 35 other manufacturers making up the rest. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 695 payments — averaging $135.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$81K
- AstraZeneca$3K
- Viiv Healthcare Company$2K
- Boehringer Ingelheim$2K
- United Therapeutics Corporation$1K
- Insmed, Inc.$620
- plus $6K from 30 others
Across 51 payments — averaging $6071.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$133K
- AstraZeneca$97K
- GSK$39K
- Mylan Specialty L.p.$24K
- Verona Pharma, Inc.$18K
What the payments were for
- Consulting fees$8201%
- Speaking & faculty fees$78,65083%
- Travel & lodging$8511%
- Food & beverage$13,94415%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 181 | $81,185 |
| AstraZeneca | 126 | $2,706 |
| Viiv Healthcare Company | 1 | $1,600 |
| Boehringer Ingelheim | 73 | $1,538 |
| United Therapeutics Corporation | 11 | $1,073 |
| Insmed, Inc. | 30 | $620 |
| Philips North America LLC | 39 | $570 |
| Electromed, Inc. | 36 | $541 |
| Grifols USA, LLC | 23 | $516 |
| Regeneron Healthcare Solutions, Inc. | 22 | $515 |
| Actelion Pharmaceuticals US, Inc. | 11 | $381 |
| Sanofi | 12 | $315 |
| Pfizer | 18 | $307 |
| Amgen | 15 | $307 |
| Intuitive Surgical | 2 | $251 |
| Johnson & Johnson | 12 | $212 |
| Shionogi Inc | 9 | $212 |
| Mallinckrodt Hospital Products Inc. | 11 | $190 |
| Verona Pharma, Inc. | 8 | $175 |
| Mylan Specialty L.p. | 8 | $171 |
| AbbVie | 5 | $145 |
| Genentech USA, Inc. | 7 | $124 |
| Inogen, Inc. | 8 | $122 |
| Sunovion Pharmaceuticals Inc. | 8 | $110 |
| Teva Pharmaceuticals USA, Inc. | 6 | $93 |
| Merck | 2 | $49 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Viatris Specialty LLC | 1 | $34 |
| Melinta Therapeutics, LLC | 1 | $33 |
| Inari Medical, Inc. | 1 | $32 |
| Pulmonx Corporation | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Tris Pharma Inc | 1 | $21 |
| Advanced Respiratory, Inc | 1 | $20 |
| Shire North American Group Inc | 1 | $19 |
| Tactile Systems Technology Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$33,128
- NUCALA$9,222
- ANORO ELLIPTA$7,200
- ANORO$3,600
- TYVASO$820
- Da Vinci Surgical System$245
- TEZSPIRE$150
- Arikayce$125
- UPTRAVI$105
- OPSUMIT$105
How this compares
$94,295 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 678 | $600,076 |
| OfevNintedanib Esylate | 12 | $157,694 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 128 | $87,692 |
| Breo ElliptaFluticasone/Vilanterol | 155 | $84,768 |
| EliquisApixaban | 66 | $58,918 |
| Spiriva RespimatTiotropium Bromide | 64 | $55,574 |
| TezspireTezepelumab-Ekko | 12 | $46,285 |
| SymbicortBudesonide/Formoterol Fumarate | 114 | $36,161 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,051 | $33,859 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 48 | $28,379 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $25,657 |
| Advair HfaFluticasone Propion/Salmeterol | 55 | $22,308 |
| XareltoRivaroxaban | 14 | $19,065 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $14,578 |
| BreynaBudesonide/Formoterol Fumarate | 33 | $9,617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $81,185 | $781,989983 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,538 | $256,224139 claims |
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere | $2,706 | $108,103150 claims |
| PfizerEliquis | $307 | $58,91866 claims |
| Johnson & JohnsonXarelto | $212 | $19,06514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Webster
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
- David MarksSan Antonio$453K
- Sandeep SahayHouston$378K
- Jefy MathewThe Woodlands$318K
- Rodolfo Estrada AnzuetoSan Antonio$300K
- Zeenat SafdarHouston$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.